Investigational drug · Phase 2
CPL500036
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Parkinson Disease, Dyskinesia, Medication-Induced.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "CPL500036"
First trial start
2021
Nov 2, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CPL500036", any sponsor or status.
Conditions studied
As listed on its trial records.
- Parkinson Disease
- Dyskinesia, Medication-Induced
Approved drugs for the same conditions: Parkinson's disease · Neurology · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "CPL500036" as an intervention, largest first.
- Efficacy, Safety and Pharmacokinetics Study of CPL500036 (PDE10A Inhibitor) in Patients With SchizophreniaPivotal-lookingCompleted
Celon Pharma SAIndustry
NCT05278156 · 189 participants · Start May 19, 2021 · Primary completion Jun 5, 2024
Drug: CPL500036 - low dose; CPL500036 - high dose and 1 more · For: Schizophrenia
Sites: Budapest, Hungary; Győr, Hungary; Kalocsa, Hungary · 16 sites in all
- Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients With Levodopa Induced DyskinesiaCompleted
Celon Pharma SAIndustry
NCT05297201 · 105 participants · Start Nov 2, 2021 · Primary completion Jan 13, 2025
Drug: CPL500036 - low dose; CPL500036 - high dose and 1 more · For: Parkinson Disease; Dyskinesia, Medication-Induced
Sites: Warsaw, Poland; Oświęcim, Poland; Cherkasy, Ukraine · 16 sites in all
Celon Pharma SAIndustry
NCT03873324 · 56 participants · Start Dec 20, 2018 · Primary completion Sep 16, 2019
Drug: CPL500036 compound; Placebo · For: Healthy Volunteers
Sites: Kajetany, Poland
Newest research
PubMed records naming it or its code names, newest first.
- PDE10A Inhibition in Schizophrenia: A Randomised, Placebo-Controlled Phase 2 Study of Alofropodect (CPL'36) in Patients Experiencing Acute Schizophrenia.
Wieczorek M, Waszkiewicz N, Gromniak-Haniecka E, et al. · CNS Drugs 2026
- Recent and on-going trials for the treatment of levodopa-induced dyskinesia: a review of the clinical trial databases.
Al-Kassmy J, Alsalmi M, Kang W, et al. · Neurodegener Dis Manag 2025
- Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?
Alsalmi M, Al-Kassmy J, Kang W, et al. · Expert Opin Pharmacother 2024
- A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects.
Matloka M, Janowska S, Pankiewicz P, et al. · Front Pharmacol 2022
- Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease.
Lenda T, Ossowska K, Berghauzen-Maciejewska K, et al. · Eur J Pharmacol 2021
Also in development for Parkinson Disease
- RadotinibSupect, IY5511Phase 33 trials
Il-Yang Pharm. Co., Ltd. · Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory
- CVN424Phase 32 trials
Cerevance · Parkinson Disease, Parkinson's Disease
- BHV-8000Phase 31 trial
Biohaven Therapeutics Ltd. · Parkinson Disease
- Human Dopaminergic Progenitor CellsNouvNeu001Phase 23 trials
iRegene Therapeutics Co., Ltd. · Parkinson Disease, Parkinson Disease (PD)
- AB-1005Phase 22 trials
AskBio Inc · PARKINSON DISEASE (Disorder), Parkinson Disease
- DNL151BIIB122Phase 22 trials
Denali Therapeutics Inc. · Parkinson Disease
- HBI-002Phase 22 trials
Hillhurst Biopharmaceuticals, Inc. · Parkinson Disease, Anemia, Sickle Cell
- VutiglabridinHSG4112Phase 22 trials
Glaceum · Knee Osteoarthritis (Knee OA), Parkinson Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.